Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:6.2.1.7 (
BAL
)
1,977
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
An examination was made of the relative efficacies of 2,3-dimercapto-1-propanol (
BAL
) and three diesters ( [CH(SH)COOR]2; DMDMS, R = CH3; DEDMS, R = C2H5; and Di-PDMS, R = CH(CH3)2] of meso-2,3-dimercaptosuccinic acid (DMSA) in mobilizing freshly injected lead from mice. These diesters, like
BAL
, reduced the lead levels resulting from freshly injected lead in both the soft tissues (liver, kidneys, spleen, and
brain)
and the bone (tibia). After treatment with the dimethyl (DMDMS), the diethyl (DEDMS), and the diisopropyl (Di-PDMS) esters the lead content of each of the organs was significantly less than that present in the untreated controls. Each of the diesters reduced lead levels in the kidneys, liver, and spleen significantly below those levels found after
BAL
treatment. The action of the diesters in reducing brain lead levels was comparable to that of
BAL
. Di-PDMS was the most effective of these compounds and was significantly superior to
BAL
. Each of the esters was also significantly more effective than
BAL
in reducing the whole body level of lead.
...
PMID:Mobilization of lead by esters of meso-2,3-dimercaptosuccinic acid. 254 77